Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2029

Conditions
Endometrial Cancer
Interventions
DRUG

Sapanisertib

Oral

DRUG

Serabelisib

Oral

DRUG

Paclitaxel

Infusion

Trial Locations (16)

12208

RECRUITING

Women's Cancer Care Associates, LLC, Albany

15224

RECRUITING

West Penn Hospital, Pittsburgh

18901

RECRUITING

Alliance Cancer Specialists, PC, Doylestown

20613

RECRUITING

Maryland Oncology Hematology, P.A., Brandywine

22031

RECRUITING

Virginia Cancer Specialists, P.C., Fairfax

33140

RECRUITING

Mount Sinai Comprehensive Cancer Center, Miami Beach

33401

RECRUITING

Florida Cancer Specialists, East, West Palm Beach

33705

RECRUITING

Florida Cancer Specialists, North, St. Petersburg

46214

RECRUITING

University of Cincinnati Medical Center, Cincinnati

55369

RECRUITING

Minnesota Oncology Hematology, P.A., Maple Grove

57105

RECRUITING

Avera Cancer Institute, Sioux Falls

77380

RECRUITING

Texas Oncology - Gulf Coast, The Woodlands

92037

RECRUITING

UC San Diego Moores Cancer Center, La Jolla

94158

RECRUITING

University of California, San Francisco (UCSF), San Francisco

97227

RECRUITING

Northwest Cancer Specialists, P.C., Portland

97401

RECRUITING

Oncology Associates of Oregon, P.C., Eugene

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Faeth Therapeutics

INDUSTRY

collaborator

GOG Foundation

NETWORK